NewLink presents HyperAcute Pancreas data

NewLink Genetics Corp. (Ames, Iowa) presented data from the open-label Phase II trial of HyperAcute Pancreas plus Gemzar gemcitabine and 5-fluorouracil (5-FU) to treat pancreatic cancer. The combination produced a one-year overall survival (OS) rate of 96% and a median disease-free survival (DFS) of about 17 months. The company said that published studies show that Gemzar plus 5-FU produce a one-year OS rate of about 70% and a median DFS of 11 months. The U.S. trial enrolled 70 patients with surgically resected pancreatic cancer. ...